A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

PubWeight™: 0.89^‹?›

🔗 View Article (PMID 27281561)

Published in Clin Cancer Res on June 08, 2016

Authors

Masahiko Yanagita¹^,2, Amanda J Redig¹^,2^,3, Cloud P Paweletz¹^,4, Suzanne E Dahlberg⁵^,6, Allison O'Connell⁵, Nora Feeney⁵, Myriam Taibi¹, David Boucher⁷, Geoffrey R Oxnard¹^,2^,3, Bruce E Johnson¹^,2^,3, Daniel B Costa²^,7, David M Jackman¹^,2^,3, Pasi A Jänne⁸^,2^,3^,4

Author Affiliations

1: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
2: Harvard Medical School, Boston, Massachusetts.
3: Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
4: Belfer Center for Applied Cancer Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
5: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
6: Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
7: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
8: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Pasi_Janne@dfci.harvard.edu.

Articles citing this ↘

Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther (2017) 0.76

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int J Mol Sci (2017) 0.75

Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. Front Med (Lausanne) (2017) 0.75

Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Med (2017) 0.75

Exosomes genetic cargo in lung cancer: a truly Pandora's box. Transl Lung Cancer Res (2016) 0.75

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol (2017) 0.75

Cell-Free DNA in Oncology: Gearing up for Clinic. Ann Lab Med (2018) 0.75

Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment. Oncotarget (2017) 0.75

The "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time use. Transl Cancer Res (2016) 0.75

Articles by these authors ⇆

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res (2016) 0.94

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. JAMA Oncol (2016) 0.75